Clinical trial • Phase I • Oncology
ABBV-969 for Prostate cancer | Metastatic castration-resistant prostate cancer
Phase I trial of ABBV-969 for Prostate cancer | Metastatic castration-resistant prostate cancer. None/Not specified-controlled. 194 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Prostate cancer | Metastatic castration-resistant prostate cancer
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 30-01-2025
- First CTIS Authorization Date
- 23-05-2025
Trial design
None/Not specified-controlled Phase I trial in France, Spain.
- Comparator
- None/Not specified
- Target Sample Size
- 194
Eligibility
Recruits 194 Vulnerable population not selected; no consent or assent details provided..
- Vulnerable Population
- Vulnerable population not selected; no consent or assent details provided.
Recruitment
- Planned Sample Size
- 194
- Recruitment Window Months
- 24
Geography
- Total Number Of Sites
- 6
- Total Number Of Participants
- 36
France
- Earliest CTIS Part Ii Submission Date
- 09-05-2025
- Latest Decision Or Authorization Date
- 18-03-2026
- Processing Time Days
- 313
- Number Of Sites
- 3
- Number Of Participants
- 18
Sites
- Site Name
- Centre Oscar Lambret
- Department Name
- Département d’Oncologie Médicale
- Principal Investigator Name
- Aurélien CARNOT
- Principal Investigator Email
- a-carnot@o-lambret.fr
- Contact Person Name
- Aurélien CARNOT
- Contact Person Email
- a-carnot@o-lambret.fr
- Site Name
- Institut Gustave Roussy
- Department Name
- Département d’Innovation Thérapeutique et d’Essais Précoces (DITEP)
- Principal Investigator Name
- Christope MASSARD
- Principal Investigator Email
- christophe.massard@gustaveroussy.fr
- Contact Person Name
- Christope MASSARD
- Contact Person Email
- christophe.massard@gustaveroussy.fr
- Site Name
- Centre Leon Berard
- Department Name
- Department of Medical Oncology
- Principal Investigator Name
- Armelle VINCENEUX
- Principal Investigator Email
- Armelle.vinceneux@lyon.unicancer.fr
- Contact Person Name
- Armelle VINCENEUX
- Contact Person Email
- Armelle.vinceneux@lyon.unicancer.fr
Spain
- Earliest CTIS Part Ii Submission Date
- 10-05-2025
- Latest Decision Or Authorization Date
- 17-03-2026
- Processing Time Days
- 311
- Number Of Sites
- 3
- Number Of Participants
- 18
Sites
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Medical Oncology Department
- Principal Investigator Name
- Joaquin Mateo Valderrama
- Principal Investigator Email
- jmateo@vhio.net
- Contact Person Name
- Joaquin Mateo Valderrama
- Contact Person Email
- jmateo@vhio.net
- Site Name
- University Hospital Virgen Del Rocio S.L.
- Department Name
- Oncology Service
- Principal Investigator Name
- Begoña Pérez Valderrama
- Principal Investigator Email
- bpvalderrama@gmail.com
- Contact Person Name
- Begoña Pérez Valderrama
- Contact Person Email
- bpvalderrama@gmail.com
- Site Name
- Hospital Universitario Hm Sanchinarro
- Department Name
- Medical Oncology Service
- Principal Investigator Name
- Irene Moreno Candilejo
- Principal Investigator Email
- irene.moreno@startmadrid.com
- Contact Person Name
- Irene Moreno Candilejo
- Contact Person Email
- irene.moreno@startmadrid.com
Sponsor
Primary sponsor
- Full Name
- AbbVie Deutschland GmbH & Co. KG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- ABBV-969
- Routes Of Administration
- Intravenously (IV) infusion
- Route
- Intravenous
- First In Human
- Yes
Related trials
Other published trials that may interest you.
- ABEMACICLIB for Prostate cancer | Metastatic castration-resistant prostate cancer
- DOCETAXEL for Prostate cancer | Metastatic castration-resistant prostate cancer
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer